Ibrutinib can improve the survival of young patients with diffuse large b-cell lymphoma

New evidence shows that adding targeted therapy ibrutinib (Imbruvica) to standard chemotherapy regimens can improve the survival time of some young patients with diffuse large b-cell lymphoma (DLBCL)

The preliminary results of the PHOENIX trial showed that ibrutinib combined with standard chemotherapy regimens did not help patients with non-gcb DLBCL live longer

"People think that the test is not working," said Louis M.

Wyndham H.

DLBCL is the most common type of lymphoma, accounting for 40% of global lymphoma cases

In the early 21st century, in order to better understand the individual differences in treatment response, researchers analyzed the patterns of gene activity in DLBCL tumors

Ibrutinib is the first targeted therapy to be evaluated for the treatment of DLBCL

Subsequently, the researchers initiated the PHOENIX trial to evaluate the effect of adding ibrutinib to R-CHOP on newly diagnosed non-gcb DLBCL patients

What remains unclear in the PHOENIX trial is whether all young patients with non-gcb diffuse large B-cell leukemia benefit from ibrutinib, or whether patients with certain genetic subtypes benefit more

They showed that most of the benefits of ibrutinib are in ABC DLBCL patients, consistent with previous studies

Young patients with the BN2 genetic subtype do not seem to benefit from the addition of ibrutinib

In addition to the exceptional response rate of MCD and N1 grade DLBCL, ibrutinib does provide benefits to some other young patients with non-gcb grade DLBCL

Dr.

"For many years, we only provided chemotherapy and rituximab to these patients," he said

Article title

Effect of Ibrutinib with R-CHOP Chemotherapy in Genetic Subtypes of DLBCL